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Introduction
Cytokines such as interferons, erythropoietin, leptin and most
interleukins signal through type 1 cytokine receptors. Because
aberrant cytokine signalling underlies many pathologies, including
immunodeficiency, metabolic disorders and cancer, temporary
cytokine receptor activation is tightly regulated. Negative-feedback
mechanisms that operate to dampen signalling after receptor
activation are very well studied. These include phosphatases (Xu
and Qu, 2008), protein inhibitors of activated STAT (PIAS)
proteins (Shuai and Liu, 2005) and the suppressor of cytokine
signalling (SOCS) family (Lavens et al., 2006). Cellular sensitivity
to cytokine signals, however, also depends on the number of
receptors present at the time of stimulation. The molecular basis
of how cells establish an appropriate number of receptors at their
cell surface is far less well understood. Cell surface exposure of
type 1 cytokine receptors is a highly dynamic process that, besides
de novo synthesis, involves endocytosis followed by recycling or
degradation. Internalised receptors, irrespective of ligand
triggering, are targeted to early endosomal compartments, followed
by sorting to recycling vesicles, signalling endosomes or
multivesicular bodies (MVBs) and lysosomes for degradation
(Jovic et al., 2010). Although ligand-induced endocytosis was
originally thought to be solely a mechanism of receptor breakdown,
receptors can remain active within endosomes and can couple to
endosome-specific signalling pathways (Sorkin and von Zastrow,
2009). Protein ubiquitylation is a major mechanism that controls
receptor internalisation, intracellular trafficking and proteasomal
and lysosomal degradation (d’Azzo et al., 2005; Hicke and Dunn,
2003). Mono-ubiquitylation of cytokine receptors and the
recruitment of ubiquitin-binding proteins serve as a regulated
sorting mechanism for internalisation and sorting into the endocytic
pathway. However, the specific ubiquitin ligases, ubiquitin-sorting
signals and ubiquitin-binding proteins that control cytokine
receptor trafficking and turnover remain poorly characterised and
vary considerably between different cytokine receptor systems
(Belouzard and Rouille, 2006; Irandoust et al., 2007; Strous and
van Kerkhof, 2002).
The number of signalling-competent receptors at the cell surface
is also determined by ectodomain shedding. Proteolytic cleavage of
cell surface receptors by transmembrane metalloproteases of the
ADAM (a disintegrin and metalloproteinase) family releases the
receptor ectodomains and renders the cells desensitised to stimulation.
ADAM10 and ADAM17 (or TNF converting enzyme, TACE), the
prototypical receptor sheddases, have been implicated in ectodomain
cleavage of cytokine receptors of different families, including the
tumor necrosis factor (TNF) and interleukin-1 (IL-1) receptor families
and the type 1 cytokine receptors (Levine, 2008). The activity of
ADAM17 is regulated by several mechanisms (for a review, see
Huovila et al., 2005) including catalytic activation and cell surface
exposure upon phosphorylation of its cytosolic domain (Diaz-
Rodriguez et al., 2002; Xu and Derynck, 2010). In addition, because
ADAM10 and ADAM17 activity is confined to cholesterol-rich
membrane microdomains (lipid rafts) (Matthews et al., 2003; Tellier
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et al., 2006), substrates must be targeted to these rafts, but the
molecular mechanisms regulating this routing remain unknown.
Ring finger protein 41 (RNF41), also referred to as E3 ubiquitin-
protein ligase neuregulin receptor degradation protein-1 (Nrdp1)
or fetal liver ring finger (FLRF) belongs to the family of single
RING (really interesting new gene) finger-containing proteins.
Members of this protein family function as E3 ubiquitin ligases.
RNF41 serves as a scaffold by coordinating ubiquitin transfer from
a ubiquitin-conjugating enzyme (E2) recruited by its N-terminal
RING domain to a specific substrate that interacts with its C-
terminal substrate binding domain. RNF41 has been implicated in
the ubiquitylation and degradation of two other E3 ubiquitin ligases:
BRUCE (Qiu et al., 2004), an inhibitor of apoptosis protein and
parkin (Zhong et al., 2005), a protein involved in the onset of
Parkinson’s disease. More recently, RNF41 was found to control
Toll-like receptor (TLR)-mediated responses through ubiquitylation
of the central adaptor MyD88 and the kinase TBK1 (Wang et al.,
2009). RNF41 also functions as a key regulator of steady-state cell
surface levels of ErbB3 and ErbB4, two receptors that are closely
related to the epidermal growth factor receptor (EGFR). RNF41
associates with these receptors independently of receptor
stimulation (Diamonti et al., 2002; Qiu and Goldberg, 2002) and
elicits ligand-independent ErbB3 ubiquitylation and degradation
(Qiu and Goldberg, 2002). The biological significance of RNF41
in ErbB3 receptor signalling is underscored by the observation that
perturbation of RNF41 activity results in enhanced ErbB3-activated
cell growth and motility of human breast carcinoma cells. Moreover,
loss of RNF41 expression correlates with in vivo overexpression
and hypersignalling of ErbB3, as commonly found in primary
human breast cancer tissue, and is related to tumor malignancy
(Yen et al., 2006). Similarly to its impact on ErbB3 and ErbB4
receptor expression and function, RNF41 can modulate ligand-
independent expression of the interleukin-3 (IL-3) and
erythropoietin (Epo) cytokine receptors (Jing et al., 2008), but the
underlying mechanism is unknown. Here, we demonstrate that
RNF41 has a generic role in type 1 cytokine receptor signalling by
controlling receptor degradation and shedding.
Results
RNF41 is an interaction partner of the leptin receptor
complex in MAPPIT screening experiments
MAPPIT (mammalian protein-protein interaction trap) is a
cytokine-receptor-based two-hybrid method that allows detection
of protein interactions in mammalian cells (Eyckerman et al.,
2001). In brief, a cytokine receptor, e.g. the leptin receptor (LR),
is rendered inactive by mutating all cytosolic tyrosines (LR-F3):
activation of the JAK–STAT signalling pathway thus depends on a
bait–prey interaction, whereby the prey is fused to functional STAT
recruitment sites (Fig. 1A). Using a FACS-based protocol, complex
prey cDNA libraries can be screened for novel interaction partners
of a selected bait (Lievens et al., 2004). It is intrinsic to this
method that preys that bind to the receptor complex independently
of the bait (e.g. to the LR cytoplasmic tail or JAK2) are identified
as technical ‘false positives’. One such frequently identified protein
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Fig. 1. Identification of RNF41 as a
LR-complex-interacting protein.
(A)Schematic outline of the
MAPPIT technique using a chimeric
EpoR-LR bait receptor (ELR-F3).
(B)HEK293T cells transfected with
an RNF41 prey arising from a
MAPPIT screen and the indicated
baits, were stimulated with Epo or
left untreated. Luciferase data of
triplicate measurements from a
representative experiment are
expressed as fold induction
(stimulated/non stimulated) ± s.d.
FLAG-tagged prey expression was
verified by western blotting.
(C)Human RNF41 structure and
sequence of its RING domain.
Arrows indicate in-frame fusion
positions with gp130 in the RNF41
prey constructs identified in MAPPIT
screens. The eight residues
constituting a functional RING
domain are underlined.
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
in screening experiments corresponded to RNF41. Fig. 1B shows
a standard MAPPIT experiment demonstrating the interaction of
an RNF41 prey with the chimeric receptor complex, irrespective
of the bait (p53 or FKBP12). Significantly, all 13 RNF41-encoding
preys identified in MAPPIT screens featured a truncated N-terminal
RING domain (Fig. 1C). An RNF41 protein lacking a functional
RING domain acts as a dominant-negative inhibitor, potentiating
ErbB3 signalling by interfering with receptor degradation (Diamonti
et al., 2002; Qiu and Goldberg, 2002). Likewise, truncated RNF41
preys might stabilise the LR–bait complexes, readily explaining
their efficient identification in MAPPIT screens.
RNF41 modulates type 1 cytokine receptor cell surface
expression and signalling
We next investigated whether modulation of RNF41 levels affected
the expression of signalling competent LRs on the cell surface.
Ectopic expression of full-length RNF41 or the dominant-negative
RNF41 RING clearly suppressed or enhanced LR cell surface
expression (Fig. 2A) and signalling (Fig. 2B), respectively.
Modulation of receptor expression was ligand independent (Fig.
2A). In addition, vector-based delivery of a short-hairpin
oligonucleotide targeting endogenous RNF41 (supplementary
material Fig. S1) enhanced LR surface expression and leptin
signalling (Fig. 2C,D). These effects were specific to RNF41
because co-expression of a knockdown-resistant RNF41 construct
(rscRNF41) (supplementary material Fig. S1) completely
normalised LR surface expression and signalling (Fig. 2C,D).
Modulation of RNF41 levels also affected STAT3 phosphorylation,
as expected (Fig. 2E). Collectively, these results show that RNF41
regulates basal cell surface expression and signalling of the LR.
Similar effects were observed for other type 1 cytokine receptors:
RNF41 expression attenuated signalling in HEK293T cells via the
endogenous leukaemia inhibitory factor receptor (LIFR) and
ectopically expressed EpoR (Fig. 3A) or via the endogenous IL-
3R complex in hematopoietic Ba/F3 cells (Fig. 3B), demonstrating
that this effect of RNF41 is not restricted to HEK293T cells.
Conversely, RNF41 RING acted as a dominant-negative inhibitor
that potentiated signalling. Similarly to the LR, knockdown of
endogenous RNF41 potentiated LIFR signalling, and expression of
the rscRNF41 construct completely reversed this effect (Fig. 3C).
The common denominator of all these receptor complexes is the
receptor-associated JAK2 kinase, suggesting a direct impact of
RNF41 on JAK2. Overexpression of RNF41 can suppress JAK2
levels (Fig. 3D), but we could not demonstrate efficient co-
immunoprecipitation between RNF41 and JAK2, or RNF41-
induced JAK2 ubiquitylation (data not shown).
Cathepsin L cleaves the leptin receptor
We next investigated the effect of RNF41 on ligand-independent
LR turnover. Both the long (LRlo) and short (LRsh) isoforms of
the LR are constitutively endocytosed and degraded in lysosomes
(Belouzard et al., 2004). To monitor LR degradation, we incubated
HEK293T cells expressing a human LRlo carrying a C-terminal
HA-tag (hLR–HA) with chloroquine, an inhibitor of intralysosomal
degradation. This led to the stabilisation of two C-terminal
fragments (Fig. 4A). These degradation products of about 42 and
46 kDa, further referred to as the C-terminal LR stubs (LR-CTS),
were generated independent of leptin stimulation. This cleavage is
conserved between species and between different LR isoforms as
a comparable 12 kDa LR-CTS was observed for the mouse LRsh
fused to a C-terminal FLAG tag (mLRsh–FLAG) (Fig. 4B). We
identified the protease involved in this cleavage using a series of
pharmacological inhibitors. HEK293T cells expressing hLRlo–HA
were first incubated with cell-permeable broad-spectrum protease
blockers, each of which inhibited one of the four large protease
classes (calpeptin and E-64d for cysteine proteases; leupeptin and
PMSF for serine proteases; pepstatin A for aspartic proteases;
GM6001 for metalloproteases). Only calpeptin and E-64d inhibited
LR-CTS formation (Fig. 4C). Cathepsins are well-characterised
cysteine proteases that are involved in protein degradation. The
cathepsin B and L inhibitor z-FA-fmk and three different specific
cathepsin L inhibitors completely blocked LR cleavage, whereas
specific inhibitors of cathepsin B, cathepsin K or cathepsin S had
no clear effect, demonstrating that cathepsin L causes cleavage of
the LR (Fig. 4D). Similar results were obtained with mLRsh–
FLAG (Fig. 4E). The size of the LR-CTS predicted cleavage close
to the transmembrane region. Subcellular fragmentation revealed
that the LR-CTS was associated with the membrane fraction (Fig.
4F), in line with juxtamembrane cleavage. Previous studies have
shown that the hLR can undergo ectodomain shedding resulting in
the generation of soluble LR. This shedding by a membrane-
associated metalloprotease was enhanced by the phorbol ester
PMA and N-ethylmaleimide (NEM) and could be blocked by the
metalloprotease inhibitor TAPI-1 (Maamra et al., 2001). However,
incubation of hLRlo–HA-expressing HEK293T cells with PMA or
NEM, or co-incubating these shedding enhancers with TAPI-1 had
no effect on the generation of LR-CTS, whereas calpeptin or a
specific cathepsin L inhibitor completely blocked its formation
(Fig. 4G). This indicates that, although processing must occur at
very closeby positions in the LR ectodomain, shedding and LR-
CTS cleavage are two independent mechanisms. Receptor
trafficking is necessary to reach the correct subcellular location for
cleavage, because incubation with Brefeldin A (BFA), an inhibitor
of Arf1 activation that blocks transport from the ER to the Golgi,
completely inhibited formation of the LR-CTS, supporting the
notion that cleavage occurs in a post-ER subcellular compartment
such as the MVBs or lysosomes (Fig. 4H).
RNF41 blocks LR-CTS cleavage and enhances leptin
receptor ectodomain shedding
Importantly, RNF41 expression completely blocked the formation
of the LR-CTS in hLR–HA-expressing HEK293T cells, without
affecting the level of full-length LRs. No similar effect was seen
for RNF41 RING, implying a crucial role for the RING domain
(Fig. 5A). Similar findings were obtained for mLRsh–FLAG (Fig.
5B). Direct inhibition of cathepsin L was ruled out because RNF41
or RNF41 RING expression did not alter the levels of
procathepsin L (42 kDa) or of its processed intermediate and active
forms (34 kDa and 26 kDa, respectively) (Fig. 5C). We conclude
that RNF41 inhibits lysosomal targeting of LRs.
Cell culture supernatants were collected from the same
transfected cells to analyse LR shedding. RNF41 expression
significantly increased soluble LR levels from hLR–HA-expressing
HEK293T cells, whereas expression of RNF41 RING had no
effect (Fig. 5D). As mentioned above, LR ectodomain shedding
can be blocked by the metalloprotease inhibitor TAPI-1 (Maamra
et al., 2001). Incubation of hLR–HA-expressing HEK293T cells
with TAPI-1 reversed the enhancing effect of RNF41 on LR
shedding (Fig. 5E). In contrast to TAPI-1, incubation with a specific
cathepsin L inhibitor had no significant effect on basal or RNF41-
induced soluble LR levels, confirming that LR ectodomain shedding
by a metalloprotease and LR cleavage by cathepsin L are two
923RNF41 controls cytokine receptor turnover
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
distinct proteolytic events. TAPI-1 is known to inhibit several
members of the ADAM family. Therefore, we tested the effect of
silencing ADAM10 and ADAM17, two typical cytokine receptor
sheddases, on RNF41-induced ectodomain shedding. Silencing of
ADAM10 and ADAM17 gene expression reversed the enhancing
effect of RNF41 on LR shedding (Fig. 5F; supplementary material
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Fig. 2. RNF41 attenuates LR surface expression and signalling. (A)Expression of RNF41 or RNF41 RING suppresses or enhances LR surface expression,
independently of leptin stimulation. FACS analysis of HEK293T cells transiently transfected with eGFP, combined with a mock vector (filled histogram) or an
expression vector encoding the LR either alone (black) or together with RNF41 (red) or RNF41 RING (green). Cells were either left untreated (left) or stimulated
with 100 ng/ml leptin (right) 24 hours before analysis. Median fluorescence intensities of eGFP-positive, APC-labelled cells were used for quantification of LR
surface expression and are presented in the inset of both panels for each transfection. (B)STAT3-responsive luciferase assay of HEK293T cells transfected with the
LR and a mock, RNF41 or RNF41 RING construct. Cells were either stimulated with leptin (grey) or left untreated (white). Absolute luciferase counts of
triplicate measurements normalised for transfection efficiency are represented (mean ± s.d.) (n3). *P<0.01 (Student’s t-test) compared with mock-transfected
cells. (C)FACS analysis of unstimulated eGFP-transfected HEK293T cells lacking LR expression (filled histogram) or cotransfected with the LR together with an
empty knockdown vector (pSR, red) or expressing RNF41 RNAi (green), together with increasing amounts (0.3; 0.8 and 1.5g) of rscRNF41. Median
fluorescence intensities of eGFP-positive, APC-labelled cells were used to quantify LR surface expression and are represented in the inset of the panel. (D)STAT3-
responsive luciferase assay of HEK293T cells transfected with the LR and an irrelevant knockdown construct (iRNAi), an empty knockdown vector (pSR) or a
knockdown vector targeting RNF41 (RNF41 RNAi), either without or with increasing amounts (0.1 and 0.5g) of a rescue RNF41 construct (rscRNF41). Cells
were either stimulated with leptin (grey) or left untreated (white). Absolute luciferase counts of triplicate measurements normalised for transfection efficiency are
represented (mean ± s.d.) (n3). *P<0.01; **P<0.05 (Student’s t-test) compared with RNF41 RNAi. (E)RNF41 modulates pSTAT3 levels. HEK293T cells
expressing the LR and the indicated RNF41 or control constructs were either left untreated or were stimulated for 10 minutes with leptin following serum
starvation. Endogenous pSTAT3 and STAT3 levels were visualised by western blotting.
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Fig. S2). Importantly, because shedding and cleavage of the LR
were studied simultaneously in the same cells, these observations
provide evidence that RNF41 re-routes the LR from lysosomal
degradation to subcellular microdomains where it is targeted by
metalloproteases of the ADAM family, resulting in ectodomain
release.
To visualise the intracellular LR redistribution predicted by such
a scenario, we performed confocal microscopy on HeLa cells that
expressed LR–FLAG. Following overnight incubation with
chloroquine, RNF41 expression impaired colocalisation between
the C-terminally FLAG-tagged LR and LAMP-1, which is a typical
lysosomal marker (Fig. 5G). Together, these findings suggest an
important impact of RNF41 on the intracellular routing of the LR.
RNF41 controls intracellular cleavage and ectodomain
shedding of the LIFR and IL-6R
We next questioned whether RNF41 controlled degradation and
shedding in a generic way, as we previously observed for JAK2-
associated cytokine receptor exposure and signalling. As seen for
the LR, chloroquine stabilised C-terminal stub fragments in
HEK293T cells expressing LIFR–HA or IL-6R–HA and
pharmacological inhibition of cathepsin L or co-expression of
RNF41 inhibited CTS formation without affecting levels of the
full-length receptor (Fig. 6A,B). Incubation with chloroquine also
stabilised another IL-6R C-terminal fragment (25 kDa) that was
insensitive to cathepsin L inhibition. However, the formation of
this fragment was also blocked by RNF41 expression, suggesting
that the responsible protease resides at the same subcellular location.
Soluble LIFR and IL-6R can be generated by alternative splicing
(Horiuchi et al., 1994; Tomida et al., 1994) or, in case of the IL-
6R, also by ectodomain shedding (Mullberg et al., 1995). Again,
as seen for the LR, RNF41 increased soluble LIFR and IL-6R
levels, whereas RNF41 RING had no similar effect (Fig. 6C,D).
This ectodomain shedding was caused by a sheddase activity
because incubation with GM6001, a general metalloprotease
inhibitor, reversed RNF41-induced ectodomain shedding of LIFR
and IL-6R (Fig. 6E,F). Induced ectodomain shedding of the IL-
6R is mainly mediated by ADAM17, whereas constitutive
shedding is mediated by ADAM10 (Matthews et al., 2003). In
contrast to silencing of ADAM17, ADAM10 silencing reversed
RNF41-induced IL-6R ectodomain shedding, which is in line
with the constitutive nature of the effects of RNF41 on receptor
shedding (Fig. 6G). TAPI-1, which inhibits shedding of LR
(Maamra et al., 2001) and IL-6R (Mullberg et al., 1995), had
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Fig. 3. RNF41 modulates signalling of several type 1 cytokine receptors. (A)Expression of RNF41 or RNF41 RING suppresses or enhances STAT signalling
of endogenously expressed hLIFR and ectopically expressed EpoR, respectively. STAT3- (left) or STAT5-dependent (right) luciferase assay of HEK293T cells
stimulated with LIF (grey, left) or Epo (grey, right) or left untreated (white). (B)STAT5-dependent luciferase assay in Ba/F3 cells, expressing the endogenous IL-
3R complex, transiently electroporated with a mock, RNF41 or RNF41 RING construct. Cells were left untreated (white) or were stimulated overnight with IL-3
(grey). (C)RNF41 knockdown potentiates endogenous LIFR STAT signalling and this effect is dose-dependently reversed by expression of a rescue RNF41
construct (rscRNF41). STAT3-responsive luciferase assay of HEK293T cells transfected with an irrelevant knockdown construct (iRNAi), an empty knockdown
vector (pSR) or a knockdown vector targeting RNF41 (RNF41 RNAi), either without or with increasing amounts (0.01 and 0.1g) of rscRNF41. Cells were either
stimulated with LIF (grey) or left untreated (white). Absolute luciferase counts of triplicate measurements normalised for transfection efficiency are represented as
mean ± s.d. (n3). *P<0.01; **P<0.05 (Student’s t-test) compared with mock-transfected sample (A,B) or iRNAi (C). (D)Etag–RNF41 expression (0.1; 0.5 and
1g) dose-dependently suppresses FLAG–JAK2 (1g) levels in HEK293T cells. -actin was used as a control for loading.
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Fig. 4. The LR is cleaved by cathepsin L. Cell lysates of HEK293T cells transiently expressing the long isoform of the human LR with a C-terminal HA-tag (hLR–
HA) or the short isoform of the mouse LR with a C-terminal FLAG-tag (mLRsh–FLAG) were analysed using western blotting (WB). (A)Cells expressing hLR–HA
were left untreated (DMSO) or were incubated overnight with chloroquine, in the absence of stimulus or in combination with leptin for 0.5 or 24 hours. (B)Cells
expressing mLRsh–FLAG were left untreated (DMSO) or were incubated overnight with chloroquine. (C,D)Cells expressing hLR–HA were left untreated (DMSO) or
were incubated overnight with chloroquine alone or together with the indicated protease inhibitors. (E)Cells expressing mLRsh–FLAG were left untreated (DMSO) or
were incubated overnight with chloroquine alone or together with cathepsin L inhibitor III. (F)The remaining C-terminal fragment is membrane anchored.
Untransfected HEK293T cells or HEK293T cells transiently expressing hLR–HA were incubated overnight with chloroquine. Cell homogenates were separated in a
nuclear (NUC), cytoplasmic (CYT), membrane (MEM) and rest fraction by differential centrifugation and analysed for the presence of the FL hLR (top square) or the
CTS (bottom square) by western blotting (WB). M, molecular weight marker. (G)Activation or inhibition of ectodomain shedding has no effect on LR cleavage by
cathepsin L. Cells expressing hLR–HA were left untreated (DMSO) or were incubated overnight with chloroquine alone or in combination with calpeptin, cathepsin L
inhibitor III, NEM or PMA with or without TAPI-1. (H)Brefeldin A (BFA) incubation blocks LR-CTS formation. Cells expressing hLR–HA were left untreated
(DMSO) or were incubated overnight with chloroquine alone or in combination with BFA. FL, full length; CTS, C-terminal stub.
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Fig. 5. RNF41 blocks formation of the LR CTS and concomitantly enhances LR shedding. (A)HEK293T cells were cotransfected with hLR–HA and increasing
amounts of Etag–RNF41 or Etag–RNF41 RING. After overnight chloroquine incubation, cell lysates were analysed using western blotting (WB). (B)HEK293T cells
were cotransfected with mLRsh–FLAG and Etag–RNF41 or Etag–RNF41 RING. After overnight chloroquine incubation, cell lysates were analysed using western
blotting (WB). FL: full length; CTS: C-terminal stub. (C)Analysis of procathepsin L (42 kDa) and cathepsin L (34 and 26 kDa) expression after RNF41 (RING)
expression. (D)Cell media supernatants from the transfectants in Fig. 5A were analysed for soluble LR levels. (E)RNF41-enhanced LR shedding is reversed by TAPI-
1. HEK293T cells transfected with hLR–HA with or without full length Etag–RNF41 were incubated overnight in starvation medium with TAPI-1 or cathepsin L
inhibitor III and soluble LR levels in the cell media supernatants were quantified. (F)RNF41-enhanced LR shedding is reversed by silencing of ADAM10 and
ADAM17. HEK293T cells, reverse transfected with siRNA targeting ADAM10 or ADAM17, were cotransfected the next day with hLR–HA with or without full-length
Etag–RNF41 and soluble LR levels in the cell media supernatants were quantified. Values are means ± s.d. (n3). *P<0.01 or **P<0.05 (Student’s t-test) compared
with –RNF41; §P<0.01 or §§P<0.05 (Student’s t-test) compared with +RNF41. (G)RNF41 reduces colocalisation of LR–FLAG with LAMP-1. HeLa cells
cotransfected with hLR–FLAG together with (bottom) or without (top) RNF41 were immunostained with anti-FLAG (green) and anti-LAMP-1 (red) antibodies
following overnight chloroquine incubation. DAPI (blue) was used to visualise the nuclei. Images were acquired by confocal microscopy.
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Fig. 6. RNF41 blocks LIFR and IL-6R cleavage by cathepsin L and enhances their shedding. (A,B)Chloroquine stabilises C-terminal LIFR and IL-6R
fragments, which are blocked by cathepsin L inhibition (left panels) or RNF41 expression (right panels). HEK293T cells transiently transfected with C-terminal
HA-tagged human LIFR (LIFR–HA) (A) or IL-6R (IL-6R–HA) (B) were left untreated (DMSO) or were incubated overnight solely with chloroquine or
together with the indicated protease inhibitors (left panels); or were cotransfected with a full-length Etag–RNF41 or Etag–RNF41 RING construct and left
untreated or incubated with chloroquine (right). Cell lysates were analysed by western blotting (WB). FL, full length; *, intermediate IL-6R cleavage product;
CTS, C-terminal stub. (C,D)RNF41 enhances LIFR (C) and IL-6R (D) shedding. Cell media supernatants from the transfectants in the right panels of Fig. 6A,B
were analysed for soluble LIFR and IL-6R levels. E-tagged RNF41 or RNF41 RING expression was verified by western blotting. (E,F)RNF41-enhanced
LIFR (E) and IL-6R (F) shedding is reversed by metalloprotease inhibitors. HEK293T cells transfected with hLIFR–HA or hIL-6R–HA with or without full-
length Etag–RNF41 were incubated overnight in starvation medium with TAPI-1 or GM6001 and soluble receptor levels in the cell medium supernatants were
quantified. E-tagged RNF41 expression was verified by western blotting. (G)RNF41-enhanced IL-6R shedding is reversed by ADAM10 silencing. HEK293T cells,
reverse transfected with siRNA targeting ADAM10 or ADAM17, were cotransfected the next day with hIL-6R–HA with or without full-length Etag–RNF41 and
soluble IL-6R levels in the cell medium supernatants were quantified. Values are means ± s.d. (n3). *P<0.01 or **P<0.05 (Student’s t-test) compared with –
RNF41; §P<0.01 or §§P<0.05 (Student’s t-test) compared with +RNF41.
Jo
ur
n
a
l o
f C
el
l S
cie
nc
e
only a partial effect on levels of soluble LIFR, indicating that
LIFR shedding involves a different metalloprotease(s). LIFR
shedding has not been shown before as a mechanism for the
generation of soluble LIFR. Together, these results support the
conclusion that RNF41 controls the routing and processing of
many type 1 cytokine receptors in a similar way.
Discussion
The E3 ubiquitin ligase RNF41 is implicated in regulating the
expression of a number of proteins with varying functions,
including membrane receptors such as the EGFR family members
ErbB3 and ErbB4 (Diamonti et al., 2002; Qiu and Goldberg, 2002)
and the Epo and IL-3 cytokine receptors (Jing et al., 2008). As an
alternative to the RNF41-mediated degradation of these receptors,
we assign a role for RNF41 in restricting basal surface expression
and signalling of three different type 1 cytokine receptors and
provide evidence that RNF41 has a crucial role in ectodomain
shedding. We initially identified RNF41 as a novel interaction
partner of the leptin receptor in MAPPIT screens, whereby its N-
terminal RING domain was invariably interrupted. Expression of
such truncated RNF41 or silencing of its transcript enhanced LR
cell surface expression and potentiated STAT signalling, whereas
expression of full-length RNF41 had the opposite effect. In line
with this, the recurrent identification of the truncated RNF41 preys
isolated in the screens might be explained by a stabilised surface
expression of the LR-derived MAPPIT bait receptor, generating
pronounced MAPPIT signals. We confirmed this initial observation
for different wild-type cytokine receptors, either transfected or
endogenously expressed in different cell types. How RNF41
physically interacts with the type 1 cytokine receptor complexes is
unclear at present. The common denominator of all receptor
complexes analysed in this study is the receptor-associated JAK2
kinase, suggesting a direct impact of RNF41 on JAK2. JAK
proteins have been shown to facilitate receptor folding, maturation
and cell surface delivery by operating as a chaperone, constituting
a quality control checkpoint in the ER or Golgi (Huang et al.,
2001; Radtke et al., 2002). In addition, JAK kinases can promote
receptor expression by decreasing basal internalisation rates (Kumar
et al., 2008; Ragimbeau et al., 2003) or enhancing recycling (Royer
et al., 2005). Furthermore, the human kinome tree shows that JAK
kinases are most closely related to the EGFR family members,
which are known targets of RNF41 (Manning et al., 2002).
Although RNF41 can suppress levels of JAK2, we could not
demonstrate efficient co-immunoprecipitation between RNF41 and
JAK2, or RNF41-induced JAK2 ubiquitylation. This suggests that
the JAK2–RNF41 interaction might be indirect and that other, so
far unknown proteins bridge RNF41- and JAK2-associated cytokine
receptor complexes. Additional studies involving protein–protein
interaction analysis, subcellular localisation of RNF41 and JAK2
and the possible role of JAK2 in receptor routing are required to
further clarify this issue.
The key finding of our study is that RNF41 controls the balance
between type 1 cytokine receptor degradation and ectodomain
shedding. For three different receptor systems (LR, LIFR and IL-
6R) we observed simultaneous inhibition of cathepsin-L-
dependent cleavage and enhanced ectodomain shedding. In line
with this, confocal imaging revealed a decrease in colocalisation
of a C-terminally tagged LR with the lysosomal marker LAMP-1
upon RNF41 expression. Together, this implies an important role
for RNF41 in cytokine receptor trafficking. Such a role for RNF41
in cargo trafficking is underscored by recent studies. RNF41 was
shown to interact with Tsg101 (Vps23), a component of the
endosomal sorting complex required for transport (ESCRT-I) that
is involved in protein sorting to late endosomal membranes and
MVBs (Markson et al., 2009; Williams and Urbé, 2007). Also,
RNF41 can interact with the deubiquitylating enzyme USP8 (also
called UBPy), which is required for maintenance of ESCRT-0
stability and endosomal sorting of ErbB3 and EGFR (Niendorf et
al., 2007; Wu et al., 2004). Its role in preventing receptor
degradation might also help to explain recent findings by Cao and
co-workers, who reported that RNF41 could differentially modulate
Toll-like receptor (TLR)-mediated responses. TLRs that reside at
the plasma membrane engage the Mal/MyD88 adaptors leading to
NF-B activation, whereas activation of IRF3 is triggered by
TRAM and TRIF adaptor-coupled endosomal TLRs. Next to
ubiquitylation of crucial components in either pathway (Wang et
al., 2009), RNF41 might promote TRAM- and TRIF-driven
signalling by preventing targeting of the endosomal TLRs to the
lysosomal degradation pathway.
In addition to alternative splicing, ectodomain shedding is a
common mechanism for the generation of soluble receptors. We
show here for the first time that LIFR is susceptible to
metalloprotease-dependent ectodomain shedding, as shown before
for LR and IL-6R (Maamra et al., 2001; Mullberg et al., 1995).
Silencing of both ADAM10 and ADAM17 (also called TACE) in the
case of the LR, or ADAM10 in case of the IL-6R reverses the
effects of RNF41 on receptor shedding. ADAM10 is responsible for
the constitutive shedding of the IL-6R (Matthews et al., 2003),
which is in line with the ligand independency of the RNF41 effects.
The sheddase activity of ADAM10 and ADAM17, was shown to be
sequestered in well-ordered membrane microdomains that are rich
in cholesterol and sphingolipids, called lipid rafts (Matthews et al.,
2003; Tellier et al., 2006). Furthermore, ADAM substrates are present
in different proportions in lipid rafts, suggesting that the entry of
these substrates in these particular membrane microdomains is
specifically regulated (Tellier et al., 2006). However, the mechanisms
or post-translational modifications modulating the entry of ADAM
substrates to these lipid rafts are still unknown. Our findings imply
that RNF41 sends receptors to such cellular domains for ectodomain
shedding. Because rerouting by RNF41 depends on its RING domain
and ubiquitin was shown to act as a sorting signal (Acconcia et al.,
2009), (mono-)ubiquitylation of cargo proteins and/or proteins
involved in the sorting machinery is probably involved. Future
studies identifying the specific ubiquitylation targets of RNF41 (e.g.
members of the ESCRT complex) will be required to unravel the
precise molecular sorting mechanism. Enhanced shedding mediated
by RNF41 expression might be directly correlated with decreased
detection of surface receptors in our FACS assay and the attenuated
signalling. However, additional effects of RNF41 on receptor stability
and degradation cannot be ruled out at present and need further
investigation.
In addition to its potentiating effect on metalloprotease-dependent
ectodomain shedding, RNF41 also affects cleavage of the LR,
LIFR and IL-6R. As shown before for the insulin receptor (IR)
and insulin-like growth factor-1 receptor (IGF-1R) (Yang et al.,
2007), we demonstrate using specific cathepsin inhibitors that both
the LR (long and short isoform), LIFR and IL-6R are cleaved
by the cysteine protease cathepsin L, leading to the formation of a
membrane-anchored C-terminal stub (CTS). Brefeldin A, an
inhibitor of ER to Golgi transport, completely blocks formation of
the LR-CTS, indicating that cleavage occurs in a post-ER
subcellular compartment such as the MVBs or lysosomes.
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Interestingly, gene deletion or pharmacological inhibition of
cathepsin L was shown to reduce body weight gain and glucose
intolerance, partly because of increased levels of muscle IR (Yang
et al., 2007). Cleavage by cathepsin L of cytokine receptors such
as the LR, might contribute to this phenotype. Increased levels of
cathepsin L in obese and diabetic patients suggest that this protease
is a novel target for these metabolic disorders.
Future studies will have to determine how endogenous RNF41
expression is regulated. RNF41 expression was shown to be a
TLR-inducible protein in RAW264.7 macrophages upon LPS
stimulation (Wang et al., 2009). Moreover, auto-ubiquitylation and
other post-transcriptional mechanisms are involved in suppressing
RNF41 stability (Ingalla et al., 2010; Wu et al., 2004).
In conclusion, we have shown that a single protein, RNF41, can
control the balance between JAK2-associated cytokine receptor
degradation and ectodomain shedding. Our findings imply that
RNF41 reroutes receptors from the lysosomal degradation pathway
to cellular compartments for ectodomain shedding. As aberrant
cytokine receptor expression and shedding has been correlated
with the onset of various pathologies (Gooz, 2010; Murphy, 2008),
a better understanding of the cellular control systems that safeguard
correct exposure and shedding of receptors might contribute to
developing therapies aimed at harnessing the associated diseases.
Materials and Methods
Constructs
The sequences encoding the human LR (hLR) and human LIFR (hLIFR) were
amplified and cloned in the pMET7 expression vector using 5-AACTGCAG-
CACCATGATTTGTCAAAAATTCTGTG-3 containing a PstI site and 5-
CTCTCTAGATTACGCATAATCCGGCACATCATACGGATACACAGTTAGGTC-
ACACAT CTTGTTTTC-3 containing a XbaI site and a HA-coding sequence to
generate pMET7-hLR-HA, and 5-CGCGAATTCATGATGGATATTTACGTAT-
GTTTG-3 containing an EcoRI site and 5-CCCTCTAGATTACGCATAATCCG-
GCACATCATACGGATAATCGTTTGGTTTGTTCTGAAAAAAG-3 containing a
XbaI site and a HA-coding sequence to generate pMET7-hLIFR-HA. The pSVL-
hIL-6R construct, encoding the human IL-6R, was from G. Müller-Newen (RWTH,
Aachen, Germany) and a C-terminal HA-tag was inserted by site-directed mutagenesis.
All bait receptors are generated based on the standard pSEL receptor construct,
containing the extracellular part of the human EpoR and the transmembrane and intra-
cellular parts of the mouse LR, that was reported elsewhere (Eyckerman et al., 2001).
To generate the ELR-F3-FKBP12 bait, the FKBP12 sequence was amplified from a
formerly constructed FKBP12 prey using a forward 5-CGCGAGAGCTCAGGAGT-
GCAGGTGGAAACCATC-3 and reverse 5-CGCTGCGGCCGCTTATTCCA GT -
TTTAGAAGCTCC-3 primer and then cloned in the standard pSEL bait receptor using
SacI and NotI. The hRNF41 (AA109-317) prey was obtained by PCR amplification of
cDNA prepared from a cell clone identified in a MAPPIT screen for proteins
interacting with the LR-F3 receptor itself (unpublished data), using primers that
recognise the sequences flanking the prey cDNA insert (Lievens et al., 2004). The
pUT651 construct expressing -galactosidase was obtained from Eurogentec. The
pGL3--casein-luci reporter construct containing five repeats of the STAT5-responsive
motif of the -casein promoter was a gift from Ivo Touw (Erasmus MC, Rotterdam,
The Netherlands). The generation of the following constructs was described
previously: pMET7-mLRsh-FLAG (Eyckerman et al., 1999), the pXP2d2-rPAPI-
luciferase reporter originating from the rPAPI (rat pancreatitis associated protein I)
promoter, ELR-F3-p53 bait (Eyckerman et al., 2001), pMET7-mLRlo-FLAG (Zabeau
et al., 2005), pSV-hEpoR (Montoye et al., 2005) and pMET7-FLAG-FKBP12
(Wauman et al., 2008). Full-length human RNF41 was amplified from HEK293T
cDNA using the forward primer 5-GCGGAATTCGCCATGGGGTATGATGTAAC-
CCG-3 containing an EcoRI site and the reverse primer 5-CGC TCTAG ATTA -
ACGCGGTTCCAGCGGGTCCGGATACGGCACCGGCGCACCCTCGAGTA TC -
TCTTCCACGCCATGCG-3 containing an XbaI site. Insertion in an EcoRI and XbaI
digested pMET7 vector generated the C-terminally E-tagged RNF41 construct. An N-
terminally E-tagged RNF41 pMet7 construct was generated using the former construct
as a template with the forward primer 5-GAGCGGCCGCTGGGTATGATGTAAC-
3 containing a NotI site and the reverse primer 5-CGCTCTAGATTATATCTCTTC-
CACGCCATGCG-3 containing an XbaI site. The amplified sequence was cloned in
a NotI-XbaI opened pMET7-Etag-mSOCS2 construct that was described previously
(Piessevaux et al., 2006). An RNF41 rescue construct was designed by site-directed
mutagenesis using the forward primer 5-GAGCTGGAGAAGACTAGTGCCGAG-
CATAAGCACCAGCTGGCGGAG-3 and the reverse primer 5-CTCCGCCAG -
CTG GTGCTTATGCTCGGCACTAGTCTTC TCC AG CTC-3. RNF41 RING
spanning amino acids 109–317 of human RNF41 were transferred from the hRNF41
(AA109–317) prey into a pMET7–FLAG vector via digestion with EcoRI and XbaI.
A similar construct with an N-terminal E-tag was obtained by replacing the RNF41
sequence starting from amino acid 1 in the pMet7-Etag-RNF41 construct with the
sequence starting from amino acid 109 in the pMet7-FLAG-RNF41 RING construct,
both flanked by NotI and BsaHI. For knockdown experiments the shRNA expression
vector, pSUPER-retro (Oligoengine) was used for expression of shRNA. The RNF41-
specific insert was a 19 nucleotide sequence corresponding to nucleotides 462–480
(5-GACGTCAGCTGAACACAAA-3) of RNF41, which was separated by a non-
complementary spacer (TTCAAGAGA) from the reverse complement of the same 19
nucleotide sequence. As a control, we used either the iRNAi construct, which targets
a sequence that bears no significant homology to any mammalian gene (5-TTCTCC-
GAACGTGTCACGT-3), or an empty pSUPER-retro vector (pSR). All constructs
were verified by DNA sequence analysis.
Cell culture, transfection procedures and protease inhibitors
HEK293T and HeLa cells were cultured in an 8% CO2 humidified atmosphere at
37°C and grown in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) with
10% fetal calf serum (Perbio). For the cleavage and shedding assays, HEK293T cells
were seeded in six-well plates (4105 cells/well) and transfected overnight with 2 g
of receptor-encoding plasmid DNA (±2 g RNF41-encoding plasmid DNA) using the
calcium phosphate method. For confocal imaging, 2105 cells/well were seeded on
No. 1.5 glass coverslips (Zeiss), coated with poly-D-lysine (Sigma). The next day,
they were transfected with JetPrime (Polyplus) according to the manufacturer’s
guidelines with 1 g of receptor-encoding plasmid DNA ±1 g of RNF41-encoding
plasmid DNA. The pMET7-SVT construct was used to normalise for the amount of
transfected DNA and load of the transcriptional and translational machinery. One day
(or 8 hours for confocal imaging) after transfection, cells were left untreated (DMSO)
or treated overnight with chloroquine (25 M), phorbol 12-myristate 13-acetate
(PMA) (1 g/ml), N-ethylmaleimide (NEM) (5 nM), E-64d (10 M), pepstatin A (10
M), z-FA-fmk (10 M) (Sigma), TAPI-1 (50 M) (Peptides International), Brefeldin
A (BFA) (5 g/ml), calpeptin, phenylmethylsulfonyl fluoride (PMSF), leupeptin,
GM6001, cathepsin L inhibitor II/III/IV, cathepsin K inhibitor II, cathepsin S inhibitor,
CA-074 Me (all at 10 M) (Calbiochem).
Ba/F3 cells were cultured in a 8% CO2 humidified atmosphere at 37°C and grown
in RPMI 1640 medium (Invitrogen) supplemented with 10% heat-inactivated fetal
calf serum (Perbio) and WEHI-3B conditioned medium (containing IL-3).
Transfections were performed by electroporation (300 V, 1500 F) (Clontech) with
the RNF41-encoding plasmids (22 g) and the pGL3--casein-luci reporter construct
(8 g).
Western blot analysis
HEK293T cells were washed twice with ice-cold PBS and lysed in modified RIPA
buffer [200 mM NaCl, 50 mM Tris-HCl, pH 8.0, 0.05% SDS, 2 mM EDTA, 1%
Nonidet P-40, 0.5% deoxycholic acid, 1 mM Na3VO4, 1 mM NaF, and Complete
protease inhibitor cocktail (Roche)]. Lysates were cleared by centrifugation at 14,000
r.p.m. for 10 minutes at 4°C. The 5 loading buffer (156 mM Tris-HCl, pH 6.8, 2%
SDS, 25% glycerol, 0.01% Bromophenol Blue sodium salt, 5% -mercaptoethanol)
was added to the cell lysates, which were then resolved by SDS-PAGE and transferred
to nitrocellulose membranes (Amersham Biosciences). Blotting efficiency was
checked by Ponceau S staining (Sigma). Blots were blocked in Odyssey blocking
buffer (Li-Cor). -actin, pSTAT3, STAT3, HA-tagged, FLAG-tagged and E-tagged
proteins were revealed using a rabbit anti--actin (Sigma), rabbit anti-pSTAT3
(Y705), mouse anti-STAT3 (124H6) (Cell Signaling), monoclonal rat anti–HA (3F10)
(Roche), mouse anti-FLAG-M2 (Sigma) and mouse anti-E-tag (Phadia) antibody,
respectively, followed by an anti-rabbit, anti-rat or anti-mouse Alexa-Fluor-680-
conjugated antibody (Molecular Probes), diluted in Odyssey blocking buffer (Li-
Cor) with 0.1% Tween-20.
Subcellular fragmentation
hLR–HA-expressing HEK293T cells were incubated overnight with chloroquine
and harvested into 500 l cell lysis buffer [10 mM HEPES, 10 mM NaCl, 1 mM
KH2PO4, 5 mM NaHCO3, 1 mM CaCl2, 0.5 mM MgCl2, 5 mM EDTA and Complete
protease inhibitor cocktail (Roche)]. Cells were allowed to swell for 5 minutes and
Dounce homogenised 50 times. After centrifugation (5 minutes, 4°C) at 7500 r.p.m.,
the pellet is the nuclei fraction (plus debris) and the supernatants is the cytosol plus
membrane fraction. The supernatant was centrifuged (30 minutes, 4°C) at 25,000
r.p.m. Pure cytosol supernatants were collected and the membrane pellet was
resuspended in 40 l PBS. The nuclei fraction was resuspended in 1 ml Tris,
Sucrose, EDTA (TSE) buffer (10 mM Tris-HCl, pH 7.5, 300 mM sucrose, 1 mM
EDTA, 0.1% NP-40 and Complete protease inhibitor cocktail), Dounce homogenised
30 times and centrifuged (5 minutes, 4°C) at 5000 r.p.m. The supernatant (rest
fraction) was collected and the pure nuclei pellet was resuspended in 40 l TSE
buffer.
ELISA for the detection of soluble cytokine receptors
In the final 24 hours before collection of the cell medium samples, cells were
cultured in DMEM without fetal calf serum. The human sLeptinR and sIL-6R
Quantikine® ELISA kit (R&D Systems) and human sLIF-R/gp190 ELISA kit
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(BioVendor) were used to determine soluble hLR, hIL-6R and hLIFR levels,
respectively, following the manufacturer’s instructions.
Luciferase reporter assays
For a typical luciferase experiment, HEK293T cells were transfected with the desired
receptor (100 ng) and RNF41 (2 g; 1 g for iRNAi, pSR and RNF41 RNAi)
constructs, together with a STAT3-dependent pXP2d2-rPAPI or STAT5-responsive
pGL3--casein luciferase reporter plasmid (200 ng). Cells were additionally
transfected with a -gal reporter construct (200 ng) to correct for transfection
efficiency. The pMET7-SVT construct was used to normalise for the amount of
transfected DNA and load of the transcriptional and translational machinery. 24
hours after transfection, HEK293T cells were washed, transferred to a 96-well plate
and left untreated or stimulated for at least 24 hours with mouse leptin (100 ng/ml),
human Epo (5 ng/ml), human IL-3 (1 ng/ml) (R&D Systems) or human LIF (10
ng/ml) (Chemicon International). Luciferase activity from triplicate samples was
measured by chemiluminescence in a TopCount luminometer (PerkinElmer) and
expressed as fold induction (stimulated/non-stimulated relative light units) or as
relative light units normalised for transfection efficiency. All luciferase data shown
are based on at least three independent experiments (n3).
FACS analysis
HEK293T cells were transiently transfected with a mock vector or an expression
vector encoding the mLR either alone (0.5 g) or together with the indicated RNF41
constructs (1.5 g). In addition, all cells were transfected with an eGFP construct (0.1
g) to allow gating for transfected cells during FACS analysis. The pMET7-SVT
construct was used to normalise for the amount of transfected DNA and load of the
transcriptional and translational machinery. 18 hours after transfection, HEK293T
cells were left untreated or stimulated for another 24 hours with 100 ng/ml mouse
leptin. Expression of the LR was monitored using a combination of two rat monoclonal
antibodies directed against the extracellular domain of the mLR, which were produced
in-house, and subsequent incubation with an anti-rat biotin (KPL) and streptavidin-
APC (BD Biosciences Pharmingen) conjugated antibody. Fluorescence activated cell
sorting (FACS) was performed on a FACSCalibur (Becton Dickinson).
Silencing of ADAM10 and ADAM17
ADAM10 siRNA (ADAM10 ON-TARGETplus SMARTpool, Dharmacon), ADAM17
siRNA (5-AAGAAACAGAGUGCUAAUUUA-3, Qiagen) and Stealth RNAi
siRNA Negative Control Med GC (Invitrogen) were reverse transfected in HEK293T
cells using Dharmafect (Dharmacon) 1 day before transfection of the plasmids
expressing the appropriate receptor or RNF41. Silencing efficiency was evaluated
using real-time PCR.
Confocal microscopy
24 hours after transfection, cells were rinsed with 1 PBS and fixed for 15 minutes
at room temperature in 4% paraformaldehyde. After three washes with 1 PBS,
cells were permeabilised with 0.1% Triton X-100 in 1 PBS for 10 minutes and
blocked in 1% BSA in 1 PBS for another 10 minutes at room temperature.
Samples were then incubated for 1 hour at room temperature with 1:500 rabbit anti-
FLAG (F7425, Sigma) and 1:500 mouse anti-LAMP-1 (H4A3, Abcam) antibodies.
After four washes in 1 PBS, cells were incubated for 1 hour at room temperature
with goat anti-rabbit Alexa Fluor 488 and goat anti-mouse Alexa Fluor 594 secondary
antibodies. Nuclei were stained with DAPI. Images were acquired using a 60 1.35
NA objective on an Olympus IX-81 laser scanning confocal microscope and analysed
using Fluoview 1000 software.
RNA isolation, cDNA synthesis and quantitative real-time PCR analysis
Total RNA was isolated from HEK293T cells using RNeasy spin columns and treated
with RNase-free DNaseI (Qiagen). Concentration and purity of the extracted RNA
were determined using the A260/A280 value measured on an ND1000
Spectrophotometer (NanoDrop Technologies). cDNA synthesis was carried out from
5 µg total RNA using SuperScript II Reverse transcriptase (Invitrogen) by the oligodT
priming method. Relative mRNA transcript levels of endogenous RNF41 were
assessed by real-time quantitative PCR using the LightCycler 480 Probes Master
(Roche) in combination with the Universal ProbeLibrary probe #25 (Roche) and PCR
primers (5-TGCCCTATTTGCAGTGGAGT-3 and 5-CGTTGCAGAAAGCAT-
GTTCA-3) (Eurogentec) specific for RNF41 and designed using the Probe Library
Assay Design Center (http://www.roche-applied-science.com/sis/rtpcr/upl/adc.jsp).
For ADAM10, probe #70 and PCR primers 5-TGTTGCTGAGAGTGTTAATTCT-
GC-3 and 5-TTAAAGGATTCCCATACTGACCTC-3; and for ADAM17, probe #78
and PCR primers 5-CCTTTCTGCGAGAGGGAAC-3 and 5-CACCTTGCA -
GGAGTTGTCAGT-3 were used. The PCR cycle parameters were an initial
denaturation of 95°C for 5 minutes and then 40 cycles of denaturation at 95°C for 10
seconds, annealing at 60°C for 15 seconds and extension at 72°C for 10 seconds. Each
sample was run as a technical duplicate. GADPH (probe #60 and primers 5-AGCCA-
CATCGCTCAGACAC-3 and 5-GCCCAATACGACCAAATCC-3) and HPRT
(probe #73 and primers 5-TGACCTTGATTTATTTTGCATACC-3 and 5-CGAG-
CAAGACGTTCAGTCCT-3) served as internal controls and were used to normalise
for differences in each sample. Relative RNF41 mRNA levels were quantified using
LightCycler 480 Software 1.5.
Statistical analysis
Data are expressed as mean ± s.d. of at least three independent experiments. For
statistical analyses of two groups, two-tailed Student’s t-tests were performed.
GraphPad Prism version 5.00 software was used for all statistical data analysis.
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